Reozalimab - CAS 2445259-99-2

Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, inhibiting the primary inhibitory receptor-ligand interaction within the PD-1 pathway. It exhibits antitumour efficacy and enhances T-cell activation in vitro.

PD-1/PD-L1

Immunology/Inflammation, Cell Cycle/Checkpoint, Apoptosis

2445158

0.981

-20°C

Ice Packs

Inhibitory Antibodies